VLA2001 (COVID-19 coronavirus vaccine)

Main article: Vaccines against COVID-19 coronavirus

2021: COVID-19 vaccine announcement with higher efficacy than AstraZeneca

On October 18, 2021, the company Valneva announced the results of the third final stage of clinical studies of the coronavirus vaccine. COVID-19 A drug called VLA2001 turned out to be more effective than that of, and AstraZeneca is preparing for mass deliveries.

The main phase 3 Cov-Compare study included 4,000 participants aged 18 years and older in 26 sites. VLA2001 demonstrated superiority over AZD1222 AstraZeneca in mean geometric titre of neutralization antibodies, as well as lack of superiority in seroconversion scores, SCR above 95% in both treatment groups, two weeks after the second vaccination in adults aged 30 years and older. Analysis of the T cell response in the subgroup of participants showed that VLA2001 induced a broad antigen-specific IFN-gamma-producing T cell reacting against S- 74.3%, N- 45.9% and M- 20.3% proteins.

Franco-Austrian Valneva released COVID-19 vaccine with higher efficacy than AstraZeneca

VLA2001 was well tolerated in most participants. The vaccine tolerance profile was significantly more favorable compared to the active comparator vaccine. Participants aged 30 years and older reported significantly fewer reported adverse events within seven days of vaccination, both with respect to injection site reactions and systemic reactions. No serious adverse events (SAEs) associated with treatment have been reported. Participants in the younger age group vaccinated with VLA2001 showed an overall safety profile comparable to the older age group.

These results support the benefits that are often associated with inactivated whole-viral vaccines, said Thomas Lingelbach, head of Valneva.

The incidence of COVID-19 cases was similar between treatment groups. The complete absence of cases of severe COVID-19 may suggest that both vaccines used in the study prevented the severe form of COVID-19.

Valneva has begun applying for initial approval with Britain's Medicines and Medical Products Regulatory Agency (MHRA) and is preparing to begin applying for conditional approval with the European Medicines Agency. The final validation of the assays required by MHRA to validate VLA2001-301 data continues and is a prerequisite for the final presentation of the clinical trial report.^[1]

Notes